Evidence map›Paper›PMID 28954755›Full record

ArticleBMJ case reports2017

Ventricular tachycardia after initiation of fingolimod.

Farah Elounais, Ahmed Aburahma, Mohammad Luay Alkotob, Samer Al Hadidi

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Farah ElounaisDepartment of Internal Medicine, Hurley Medical Center, Flint, Michigan, USA.
Ahmed AburahmaDepartment of Internal Medicine, Hurley Medical Center, Flint, Michigan, USA.
Mohammad Luay AlkotobDepartment of Cardiology, Hurley Medical Center, Flint, Michigan, USA.
Samer Al HadidiDepartment of Internal Medicine, Michigan State University/Hurley Medical Center, Flint, Michigan, USA.ORCID http://orcid.org/0000-0003-4297-8042
Hurley Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fingolimod, a sphingosine-1-phosphate receptor modulator, is used for the treatment of relapsing-remitting multiple sclerosis. It is well known to cause bradyarrhythmias. We present a 63-year-old woman who was admitted to the hospital with sustained monomorphic ventricular tachycardia 2 weeks after fingolimod initiation. Further evaluation showed that the patient's ventricular tachycardia was most likely secondary to her medication. Medical practitioners need to be aware of such possible life-threatening side effects while using fingolimod.

Indexed as

Diagnosis, DifferentialElectrocardiographyFemaleFingolimod HydrochlorideHumansImmunosuppressive AgentsMiddle AgedMultiple Sclerosis, Relapsing-RemittingTachycardia, VentricularFingolimod HydrochlorideImmunosuppressive Agentsarrhythmiasdrugs and medicinesneurology

Identifiers

PMID28954755
PMCPMC5747764
OpenAlexW2757461272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.